Understanding cancer drug choices survey
Part of Cancer clinical trials.
This study surveys adults with cancer experience about how they value new cancer drugs, helping doctors better communicate treatment options. Your responses could improve how benefits and risks are explained to future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have or have had cancer (excluding nonmelanoma skin cancer)
- You live in the United States
- You are fluent in English
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study asks people who have or have had cancer to share their thoughts on how much a cancer drug may extend life. It aims to understand patient expectations about survival benefits.
This study looks at how to explain the benefits and risks of new cancer drugs in a way that is easier to understand. It helps researchers learn how to communicate better with patients like you.
This study tests a digital tool that uses pictures and simple visuals to help you understand your cancer treatment options. The goal is to make the experience better for you, your family, and your doctors.
This is a survey study to understand the needs of young adults (ages 15-39 at diagnosis) who have had cancer treatment. Your answers will help improve care for others like you.
This trial is testing a questionnaire about language used in cancer care. You may be able to help by filling out a survey if you are 18+ and receiving palliative care or ongoing anti-cancer treatment.
This British Columbia study looks at how well different cancer treatments work in real life when doctors aren't sure which option is best. You and your doctor would choose a treatment, and researchers will track your results to help others.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.